Comparison Of Evidence-Based Medicine Guidelines As Defined By The EAU And AUA UroToday.com - Dr. Gunnar Aus (Gothenburg) presented an update on the EAU guidelines. Guidelines are related to evidence-based
medicine (EBM) which is the "conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients" (Sackett, DL, 1996, BMJ).
Source: www.medicalnewstoday.comForecasting Physicians' Choice Of Prescriptions? Ask Their Patients, Says Management Insights Study Physicians' choice of
prescriptions are often influenced by patients, with patient experience with specific
drugs playing a strong role, according to the Management Insights feature in the current issue of Management Science, the flagship journal of the Institute for Operations Research and the Management Sciences (INFORMS�).
Source: www.medicalnewstoday.comMaintenance Bacillus Calmette-Guerin Immunotherapy For TaG3 Or T1G3 And/or Carcinoma In Situ Transitional Cell Carcinoma Of The Bladder UroToday.com - On behalf of the Spanish CUETO study group, Dr. Martinez-Pineiro presented multicenter data on a new BCG schedule with the intent to lower toxicity. Patients in the study had TaG3 or T1G3 transitional cell carcinoma of the bladder and/or carcinoma in situ.
Source: www.medicalnewstoday.comPotential Treatment For Multiple Sclerosis Begins Clinical Trials A potential treatment for multiple sclerosis (MS), developed by University of Greenwich in association with Kings College, London, has begun clinical trials. The life sciences company BTG plc, which has licensed the research, is running the trials on a new compound, known as BGC20-0134.
Source: www.medicalnewstoday.comMolecular Detection Of Lymph Node Involvement In Genitourinary Cancer UroToday.com - Dr. Michael Jewett (Toronto) presented the SIU lecture on detection and mapping regional lymph nodes (LN) in genitourinary cancer. He addressed the importance of LN in staging and therapy of GU cancers. Staging is prognostic and sets the scenario for adjuvant therapy. Lymphadenectomy (LA) is therapeutic and should be performed.
Source: www.medicalnewstoday.comManagement Of Superficial Bladder Tumors: Group Study Comparing Epirubicin, Bacillus Calmette-Guerin (BCG), And BCG Plus Isoniazid UroToday.com - Long-term efficacy results of EORTC GU group study 30911 comparing epirubicin, bacilus calmetteguerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage Ta T1 papillary carcinoma of the bladderDr. Sylvester from the EORTC presented a study on the benefit of BCG relative to chemotherapy for long term endpoints, primarily in intermediate risk patients.
Source: www.medicalnewstoday.com
# posted by Network @ 10:00 AM
